Oncopeptides AB (publ) (STO:ONCO)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.960
+0.094 (5.04%)
May 13, 2025, 5:29 PM CET

Oncopeptides AB Company Description

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.

Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients.

Its PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.

It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma.

The SPiKE platform designed to bind to both NK-cells and specific targets on various cancer cells. It is in late preclinical development for both solid tumors and hematologic malignancies.

Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Oncopeptides AB (publ)
Oncopeptides AB logo
Country Sweden
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 80
CEO Sofia Heigis

Contact Details

Address:
Luntmakargatan 46
Stockholm, 111 37
Sweden
Phone 46 86 15 20 40
Website oncopeptides.com

Stock Details

Ticker Symbol ONCO
Exchange Nasdaq Stockholm
Fiscal Year January - December
Reporting Currency SEK
ISIN Number SE0009414576
SIC Code 2836

Key Executives

Name Position
Sofia Heigis M.Sc. Chief Executive Officer
Prof. Rolf Larsson M.D., Ph.D. Founder
Prof. Rolf Lewensohn M.D., Ph.D. Founder
Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. Founder
Dr. Kristina Luthman Ph.D. Founder
Prof. Hans Ehrsson M.D. Founder
Peter Nygren Founder
Henrik Bergentoft Chief Financial Officer
Eva Nordström M.Sc., MSc Pharm Chief Operating Officer and Deputy MD
Dr. Jakob Lindberg Med. Lic Chief Scientific Officer